Proteomics: Recent applications and new technologies

被引:40
作者
Elrick, Mollisa M. [1 ]
Walgren, Jennie L. [1 ]
Mitchell, Michael D. [1 ]
Thompson, David C. [1 ]
机构
[1] Pfizer Inc, Worldwide Safety Sci, Chesterfield, MO 63017 USA
关键词
D O I
10.1111/j.1742-7843.2006.pto_391.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Interest in proteomics as a tool for drug development and a myriad of other applications continues to expand at a rapid rate. Proteomic analyses have recently been conducted on tissues, biofluids, subcellular components and enzymatic pathways as well as various disease and toxicological states, in both animal models and man. In addition, several recent studies have attempted to integrate proteomics data with genomics and/or metabonomics data in a systems biology approach. The translation of proteomic technology and bioinformatics tools to clinical samples, such as in the areas of disease and toxicity biomarkers, represents one of the major opportunities and challenges facing this field. An ongoing challenge in proteomics continues to be the analysis of the serum proteome due to the vast number and complexity of proteins estimated to be present in this biofluid. Aside from the removal of the most abundant proteins, a number of interesting approaches have recently been suggested that may help reduce the overall complexity of serum analysis. In keeping with the increasing interest in applications of proteomics, the tools available for proteomic analyses continue to improve and expand. For example, enhanced tools (such as software and labeling procedures) continue to be developed for the analysis of 2D gels and protein quantification. In addition, activity-based probes are now being used to tag, enrich and isolate distinct sets of proteins based on enzymatic activity. One of the most active areas of development involves microarrays. Antibody-based microarrays have recently been released as commercial products while numerous additional capture agents (e.g. aptamers) and many additional types of microarrays are being explored.
引用
收藏
页码:432 / 441
页数:10
相关论文
共 58 条
[31]   Numerical approaches for quantitative analysis of two-dimensional maps: A review of commercial software and home-made systems [J].
Marengo, E ;
Robotti, E ;
Antonucci, F ;
Cecconi, D ;
Campostrini, N ;
Righetti, PG .
PROTEOMICS, 2005, 5 (03) :654-666
[32]   New directions of miniaturization within the biomarker research area [J].
Marko-Varga, GA ;
Nilsson, J ;
Laurell, T .
ELECTROPHORESIS, 2004, 25 (21-22) :3479-3491
[33]   Aptamers in research and drug development [J].
Mayer, G ;
Jenne, A .
BIODRUGS, 2004, 18 (06) :351-359
[34]   A proteomic investigation of drug-induced steatosis in rat liver [J].
Meneses-Lorente, G ;
Guest, PC ;
Lawrence, J ;
Muniappa, N ;
Knowles, MR ;
Skynner, HA ;
Salim, K ;
Cristea, I ;
Mortishire-Smith, R ;
Gaskell, SJ ;
Watt, A .
CHEMICAL RESEARCH IN TOXICOLOGY, 2004, 17 (05) :605-612
[35]  
Merrell Karen, 2004, J Biomol Tech, V15, P238
[36]   Peptide arrays: towards routine implementation [J].
Min, DH ;
Mrksich, M .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2004, 8 (05) :554-558
[37]   A proteomic analysis of human hemodialysis fluid [J].
Molina, H ;
Bunkenborg, J ;
Reddy, GH ;
Muthusamy, B ;
Scheel, PJ ;
Pandey, A .
MOLECULAR & CELLULAR PROTEOMICS, 2005, 4 (05) :637-650
[38]   Use of proteomic patterns in serum to identify ovarian cancer [J].
Petricoin, EF ;
Ardekani, AM ;
Hitt, BA ;
Levine, PJ ;
Fusaro, VA ;
Steinberg, SM ;
Mills, GB ;
Simone, C ;
Fishman, DA ;
Kohn, EC ;
Liotta, LA .
LANCET, 2002, 359 (9306) :572-577
[39]   Characterization of the human urinary proteome: A method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots [J].
Pieper, R ;
Gatlin, CL ;
McGrath, AM ;
Makusky, AJ ;
Mondal, M ;
Seonarain, M ;
Field, E ;
Schatz, CR ;
Estock, MA ;
Ahmed, N ;
Anderson, NG ;
Steiner, S .
PROTEOMICS, 2004, 4 (04) :1159-1174
[40]  
Raman B, 2002, ELECTROPHORESIS, V23, P2194, DOI 10.1002/1522-2683(200207)23:14<2194::AID-ELPS2194>3.0.CO